Published in Medical Devices and Surgical Technology Week, February 8th, 2004
In exchange, Aventis Pasteur has made a $3 million cash payment to Genome Therapeutics.
"S. pneumoniae is one of the most frequent causes of respiratory tract infections today and has been shown, in many cases, to be resistant to the commonly used antibiotics. "We are committed to leveraging the technologies available to us to develop a vaccine that is effective in preventing infections...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.